BioSpace News Archive

After consultation with leaders in organized dentistry, the Pennsylvania Department of Health has released updated guidelines for dental practices in Pennsylvania.

Vyripharm Biopharmaceuticals announced that it will repurpose the development of a novel theranostic platform for the diagnosis, monitoring and treatment of viral infections such as SARS, MERS and COVID-19.

Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2019.

BIOLASE, Inc., the global leader in dental lasers, reported net revenue of $10.2 million and $37.8 million for the fourth quarter and year ended December 31, 2019, respectively.

Equillium, Inc. (Nasdaq: EQ), today announced financial results for the fourth quarter and full-year ended December 31, 2019 and provided an update on its clinical development programs.

Revance Therapeutics, Inc., a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection, provided a corporate update given the ongoing COVID-19 situation.

Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA) (the “Company” or “Dicerna”), a leading developer of ribonucleic acid interference (RNAi) therapies, today provided an overview of its response to the COVID-19 pandemic and an update on business continuity and clinical development milestones

Enanta Pharmaceuticals, Inc., a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, reported an update on its clinical trial activities in response to the COVID-19 pandemic.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today reported its financial results for the full year ended December 31, 2019 and provided a business update.

CG Oncology, Inc. has announced today an exclusive license, development and commercialization agreement with Kissei Pharmaceutical Co., Ltd. (“Kissei”) for its oncolytic immunotherapy drug CG0070 for Japan, South Korea, Taiwan and other Asian countries with the exception of China.